ASPV = the pain in my ass!
I have to say i’ve been doing very well these past few months. Called the rally and pretty much all my trades have been winners w/the exception of one PALM (stock) trade and of course ASPV!
I’ve never seen a company make so much money, yet so hated by wall street and get pounded even further.
The company announced CellCept did not meet its MG primary and secondary endpoints w/in the 36month trial. The FDA sponsored trial already failed, so this should not be a huge surprise.
Why this is important, and negative for the company/stock…
1. this puts into question what ASPV is doing. Why did they think 36 months would do better than 12 months? Whatever they saw that indicated this to them was wrong.
2. Can they be wrong about CellCept w/the other off label use. We know for a fact that CellCept is being used, but could these failed studies make doctors question and ultimately hinder off label use?
3. Could our revenue short fall be due to number 2?
The chart is telling me more negativity, and i thought that way after the FDA sponsored MG failure. This is not good for a one product company. They need to do something asap to increase shareholder value and a purpose to keep investors.
Here is the chart…
